Understanding the safety of new cancer drugs before they are tested in people
CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIO
This study is looking at the safety of new small molecule drugs that could help treat cancer and other conditions, and it brings together experts to make sure these drugs are safe before they are tested on people, which could lead to better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iit Research Institute NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10710462 on NIH RePORTER |
What this research studies
This research focuses on the initial steps of evaluating the safety of small molecule drugs designed to treat cancer and other conditions. It involves organizing meetings to discuss the preclinical toxicology of these drugs, which is crucial for ensuring they are safe for future clinical trials. Patients may benefit from this research as it aims to develop safer and more effective cancer treatments. The approach includes collaboration among researchers and stakeholders to ensure thorough evaluation before human testing.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancer or those at risk of developing cancer who are interested in new treatment options.
Not a fit: Patients who are not diagnosed with cancer or do not have a related condition may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer cancer treatments that minimize side effects for patients.
How similar studies have performed: Similar research in preclinical toxicology has shown promise in improving the safety profiles of new cancer therapies, indicating a potential for success in this area.
Where this research is happening
Chicago, United States
- Iit Research Institute — Chicago, United States (Active)
Researchers
- Principal investigator: Mccormick, David — Iit Research Institute
- Study coordinator: Mccormick, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.